Neopharm Ltd Stock Current Valuation
| 092730 Stock | KRW 12,000 90.00 0.74% |
Valuation analysis of NeoPharm LTD helps investors to measure NeoPharm's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that NeoPharm's price fluctuation is very steady at this time. Calculation of the real value of NeoPharm LTD is based on 3 months time horizon. Increasing NeoPharm's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since NeoPharm is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NeoPharm Stock. However, NeoPharm's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 12000.0 | Real 10439.1 | Hype 12000.0 |
The real value of NeoPharm Stock, also known as its intrinsic value, is the underlying worth of NeoPharm LTD Company, which is reflected in its stock price. It is based on NeoPharm's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of NeoPharm's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of NeoPharm LTD helps investors to forecast how NeoPharm stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NeoPharm more accurately as focusing exclusively on NeoPharm's fundamentals will not take into account other important factors: NeoPharm LTD Company Current Valuation Analysis
NeoPharm's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current NeoPharm Current Valuation | 153.58 B |
Most of NeoPharm's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NeoPharm LTD is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, NeoPharm LTD has a Current Valuation of 153.58 B. This is much higher than that of the Personal Products sector and significantly higher than that of the Consumer Staples industry. The current valuation for all Republic of Korea stocks is notably lower than that of the firm.
NeoPharm Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NeoPharm's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NeoPharm could also be used in its relative valuation, which is a method of valuing NeoPharm by comparing valuation metrics of similar companies.NeoPharm is currently under evaluation in current valuation category among its peers.
NeoPharm Fundamentals
| Return On Equity | 13.82 | |||
| Return On Asset | 0.11 | |||
| Profit Margin | 0.21 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 153.58 B | |||
| Shares Outstanding | 7.99 M | |||
| Shares Owned By Insiders | 38.94 % | |||
| Shares Owned By Institutions | 17.81 % | |||
| Price To Earning | 42.54 X | |||
| Price To Sales | 1.56 X | |||
| Revenue | 87.93 B | |||
| Gross Profit | 58.64 B | |||
| EBITDA | 24.3 B | |||
| Net Income | 17.71 B | |||
| Cash And Equivalents | 7.05 B | |||
| Total Debt | 101.79 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 4.20 X | |||
| Book Value Per Share | 4,777 X | |||
| Cash Flow From Operations | 21.68 B | |||
| Earnings Per Share | 576.00 X | |||
| Target Price | 36000.0 | |||
| Number Of Employees | 106 | |||
| Beta | 1.11 | |||
| Market Capitalization | 156.02 B | |||
| Total Asset | 143.41 B | |||
| Retained Earnings | 19.71 B | |||
| Working Capital | 16.77 B | |||
| Current Asset | 22.83 B | |||
| Current Liabilities | 6.06 B | |||
| Annual Yield | 0.03 % | |||
| Net Asset | 143.41 B |
About NeoPharm Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NeoPharm LTD's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NeoPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NeoPharm LTD based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Other Information on Investing in NeoPharm Stock
NeoPharm financial ratios help investors to determine whether NeoPharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in NeoPharm with respect to the benefits of owning NeoPharm security.